Loading patent…
AssigneeSecond Genome, Inc.
InventorsBum-Yeol Hwang, Michi Izumi Willcoxon, Helena Kiefel, Toshihiko Takeuchi, Dhwani Haria, Michelle Lin, Roberta L. Hannibal, Joanna Catherine Ceolane Dreux, Jayamary Divya Ravichandar
Estimating the term…
The disclosure provides peptides and pharmaceutical compositions thereof. Such peptides can be useful, for example, in treating various human diseases such as immunological diseases. In some embodiments, the peptides are useful as immunotherapeutics for modulating regulatory and effector molecules of the mammalian immune system.
A method for identifying a subject as having a decreased likelihood of positively responding to treatment with an immunomodulator, the method comprising:
A method for identifying a subject as having an increased likelihood of having a positive response to treatment with an immunomodulator, the method comprising:
A peptide comprising an amino acid sequence having at least 60% sequence identity to SEQ ID NO:
A peptide comprising the amino acid sequence of SEQ ID NO:
A peptide comprising the amino acid sequence set forth in, X1X2SX4AKX7KX8HDHX12X13X14GRX15RX16PX18WHDWX20X21X22 (SEQ ID NO:115), wherein each of X1-X22 is independently selected from any naturally occurring amino acid.
The peptide of claim 180, wherein X1 is an amino acid selected from the group consisting of:
A peptide comprising an amino acid sequence having at least 60% sequence identity to SEQ ID NO:
A peptide comprising the amino acid sequence set forth in, X1KX3X4X5SVKX9X10CX12X13CX14X15X16IXBRX20GX22X23X24X25IX27X28X29PX31HKQX35QX37 (SEQ ID NO:161), wherein X1 is optional, each of X2-X25 and X28-X35 is independently a naturally occurring amino acid, X27 is selected from the group consisting of C and CP;
The peptide of any one of claims 125-129, wherein the one or more target proteins is selected from the group consisting of a CCR9 protein, a CHRM5 protein, a CXCR3 protein, a CXCR4 protein, a HCRTR2 protein, a MRGPRX2 protein, a SSTR1 protein, or a TSHR(L) protein.
The method of any one of claims 133-152, wherein the composition is formulated for rectal administration.
The method of any one of claims 116, 121, 156-159, wherein the treatment for cancer and/or adjunct therapy comprises surgery, radiation therapy, or a combination thereof.
Dependencies are inferred from the claim text.